Business
OPKO Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
MIAMI, Dec. 19, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) announced today that management will be participating in the 38th Annual J.P. Morgan
About this update from Opko Health, Inc.
[{"type":"text","content":"MIAMI, Dec. 19, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) announced today that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15 at 10:30 a.m. Pacific time (1:30 p.m. Eastern time).\n The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here. About OPKO Health, Inc.OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is one of the nation's largest full-service clinical laboratories; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to assess a patient’s individual risk for aggressive prostate cancer following an elevated PSA and to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity reported positive data from a Phase 2 clinical trial. It’s among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications. The company’s most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, successfully met its primary endpoint and key secondary endpoints in a Phase 3 study and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad. More information is available at www.opko.com Cautionary Statement Regarding Forward-Looking StatementsThis press release contains \"forward-looking statements,\" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as \"expects,\" \"plans,\" \"projects,\" \"will,\" \"may,\" \"anticipates,\" \"believes,\" \"should,\" \"intends,\" \"estimates,\" and other words of similar meaning, including non-historical statements about our expectations, beliefs or intentions regarding our...